SECTION 1 – Chemical Product and Company Identification
CATALYST SYSTEMS CHEMTREC: 1-800-424-9300 U S Chemical & Plastics Alco Industries Companies PO Box 88 2290 Zimmerman Rd SE Gnadenhutten, OH 44629 PH: 740-254-4311 PRODUCT NAME: CREAM HARDENER PRODUCT CODE: 27640/White, 27641/Red, 27642/Green, 27643/Blue, 28050/Black, 28070/Lt. Red Additional Product Codes on Page 4. SYNONYM/CROSS REFERENCE: Polyester Cream Hardener/Polyester Catalyst, Benzoyl Peroxide Paste SCHEDULE B NUMBER: 3815.90.0000 SECTION 2 – Hazard Identification
OVEREXPOSURE EFFECTS ACUTE EFFECTS: EYES: Contact with eyes can cause irritation, redness, tearing, blurred vision, and/or swelling. SKIN: Contact with skin can cause irritation, (minor itching, burning, and/or redness), dermatitis, defatting may be readily absorbed through the skin. INHALATION: Inhalation of vapors can cause nasal and respiratory irritation, dizziness, weakness, fatigue, nausea, headache, possible unconsciousness, and/or asphyxiation. Aspiration of material into lungs may result in chemical pneumonitis which can be fatal.
INGESTION: Ingestion can cause gastro-intestinal irritation, nausea, vomiting, diarrhea. PRIMARY ROUTES OF EXPOSURE: Skin, inhalation SECTION 3 – Composition, Information or Ingredients
INGREDIENTS
SECTION 4 – First Aid Measures
INHALATION: If inhaled, remove victim from exposure to a well-ventilated area. Make them comfortably warm, but not hot. Use oxygen or artificial respiration as required. Consult a physician. SKIN: For skin contact, wash promptly with soap and excess water. EYES: For eye contact, flush promptly with excess water for at least fifteen minutes. Consult a physician. INGESTION: If ingested, do not induce vomiting. Give victim a glass of water. Call a physician immediately. SECTION 5 – Fire-Fighting Measures
FIRE EXTINGUISHING MEDIA: Carbon dioxide, dry chemical, foam SPECIAL FIRE FIGHTING PROCEDURES: Fight like a fuel oil fire. Cool fire exposed containers with water spray. Firefighter should wear OSHA/NIOSH approved self-contained breathing apparatus.
Cream Hardener.doc Print Date: 6/4/2012 Page 1 of 5
UNUSUAL FIRE AND EXPLOSION HAZARD: Closed containers exposed to high temperatures, such as fire conditions may rupture. SECTION 6 – Accidental Release Measures
SPILLS, LEAK OR RELEASE: Ventilate area. Remove all possible sources of ignition. Avoid prolonged breathing of vapor. Contain spill with inert absorbent. SECTION 7 – Handling and Storage
STORAGE AND HANDLING: Use with adequate ventilation. Avoid contact with eyes and skin. Avoid breathing vapors. Do not store the product above 100°F/38°C. Do not flame, cut, braze weld or melt empty containers. Keep the product away from heat, open flame, and other sources of ignition. Avoid contact with strong acids, alkalis, and oxidizers. SECTION 8 – Exposure Controls and Personal Protection
INGREDIENTS
*Refer to 29 CFR 1910.0000, subpart Z. Also see TLV for Chemical Substances and Physical Agents in the Work Environment (ACGIH). RESPIRATORY PROTECTION: If component TLV limits are exceeded, use NIOSH/MSHA approved respirator to remove vapors. Use an air-supplied respirator if necessary. VENTILATION: Use adequate ventilation in volume and pattern to keep TLV/PEL below recommended levels. Explosion-proof ventilation may be necessary. PROTECTIVE GLOVES: To prevent prolonged exposure use rubber gloves; solvents may be absorbed through the skin. EYE PROTECTION: Safety Glasses or goggles with splash guards or side shields. OTHER PROTECTIVE EQUIPMENT: Wear protective clothing as required to prevent skin contact. SECTION 9 – Physical and Chemical Properties
STABILITY: Stable CONDITIONS TO AVOID: Open flames, sparks, heat, electrical and static discharge. INCOMPATIBILITY MATERIALS TO AVOID: Strong acids, alkalis, oxidizers. HAZARDOUS DECOMPOSITION PRODUCTS: Carbon Dioxide, Carbon Monoxide, and Carbon. HAZARDOUS POLYMERIZATION: Will not occur. SECTION 11 – Toxicological Information
CHRONIC EFFECTS: Overexposure to this material has apparently been known to cause the following effects in lab animals: skin damage and tumors.
CARCINOGEN: YES __ NO X TERATOGEN: YES __ NO X MUTAGEN: YES __ NO X Benzoyl Peroxide has caused tumorogenic effects in laboratory animals. SECTION 12 – Ecological Information
None. SECTION 13 – Disposal Considerations
WASTE DISPOSAL: Dispose of in accordance with local, state, and federal regulations. SECTION 14 – Transport Information
For Ground Transport: In USA – In inner containers less than 500 grams each: Consumer Commodity ORM-D or Limited Quantity. In large containers, UN3108, Organic Peroxide Type E, Solid (≤ 52% Dibenzoyl Peroxide as a paste), 5.2, PG II. For Air Transport: Must be re-boxed to UN specified packaging. UN3108, Organic Peroxide Type E, Solid (≤ 52% Dibenzoyl Peroxide as a paste), 5.2, Packaging Instruction 570. For Ocean Transport: UN3108, Organic Peroxide Type E, Solid, 5.2, EMS#F-J, S-R (the activator is ≤ 52% Dibenzoyl Peroxide as a paste). Limited quantity if inner containers are less than 500 grams each. SECTION 15 – Regulatory Information
CALIFORNIA PROPOSITION 65: This product does not contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm. SECTION 313 SUPPLIER NOTIFICATION:
Cream Hardener.doc Print Date: 6/4/2012 Page 3 of 5
This product contains the following toxic chemicals subject to the reporting requirements of the Emergency Planning and Community Right-To-Know Act of 1986 and 40 CFR 372: CHEMICAL NAME
This information must be included in all MSDS that are copied and distributed for this chemical. SECTION 16 – Other Information
HMIS RATING:
NOTE: ADDITIONAL PART NUMBERS: Bulk Red
27641 27008, 27010, 27020, 27027, 27110, 27120, 27121, 27125, 27169, 27170, 27172, 27173, 27174, 27607, 27604, 27607, 27610, 27616, 27626, 27632, 27644, 27649, 27663, 27673, 27690, 27690-1, 27697, 27750, 27751, 28015, 28016, 28028, 28139, 28144, 28149, 28164, 28187
27032, 27034, 27111, 27128, 27171, 27633, 27656, 28071, 28143, 28148,
27643 27012, 27022, 27041, 27112, 27115, 27122, 27160, 27603, 27606, 27619, 27622, 27628, 27634, 27646, 27665, 27675, 27676, 27677, 27678, 27679, 28029, 28030, 28136, 28141, 28146, 28151, 28156, 28159, 28163, 28165, 28167 27640 27014, 27024, 27036, 27038, 27114, 27124, 27132, 27168, 27201, 27211, 27621, 27627, 27647, 27648, 27664, 27674, 28025, 28031, 28042, 28043, 28059, 28145, 28150, 28171, 28184, 28185
27031, 27035, 27037, 27624, 27669, 28032, 28052, 28183, 28186
Cream Hardener.doc Print Date: 6/4/2012 Page 4 of 5
ABBREVIATIONS IARC = International Agency for Research on Cancer ACGIH = American Conference of Governmental Industrial Hygienists NIOSH = National Institute of Occupational Safety and Health TLV = Threshold Limit Value PEL = Permissible Emission Level DOT = Department of Transportation NTP = National Toxicology Program N/AV = Not Available N/AP = Not Applicable N/E = Not Established N/D = Not Determined CATALYST SYSTEMS
The information in the Material Safety Data Sheet has been compiled from our experience and from data presented in various technical publications. It is the user’s responsibility to determine the suitability of this information for the adoption of the safety precautions as may be necessary. We reserve the right to revise Material Safety Data Sheets from time to time as new technical information becomes available. The user has the responsibility to contact the Company to make sure that the MSDS is the latest one issued.
Cream Hardener.doc Print Date: 6/4/2012 Page 5 of 5
Mitochondrial DNA Subhaplogroups L0a2 and L2aModify Susceptibility to Peripheral Neuropathy inMalawian Adults on Stavudine Containing HighlyElizabeth Kampira, MSc,*† Johnstone Kumwenda, FRCP,‡ Joep J. van Oosterhout, MD, PhD,‡§independently associated with reduced risk of PN (odds ratio,Background: Peripheral neuropathy (PN) is one of the main0.39; 95% confidence interval, 0.16 t
ANLAGENArznei- und Heilmittelvereinbarung für Anlagen – Arznei- und Heilmittelvereinbarungen 2008 KV Hamburg zur Arznei- und Heilmittelvereinbarung 2008 Anpassungsfaktoren nach § 84 Absatz 2 SGB V für den Bereich der Arznei- und Verbandmittel (unter Berücksichtigung der Anlagen 1 und 2 der Rahmenvorgaben nach § 84 Absatz 7 SGB V – Arzneimittel – für das Jahr 2008 vom 17.09.2